OncoMatch/Clinical Trials/NCT05898646
Daratumumab Maintenance Therapy for Improving Survival in Patients With Light Chain Amyloidosis, EMILIA Trial
Is NCT05898646 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Daratumumab for al amyloidosis.
Treatment: Daratumumab — This phase II trial compares shorter-duration versus longer-duration maintenance therapy with daratumumab for improving survival in patients who have received initial treatment with daratumumab for light chain (AL) amyloidosis. Maintenance therapy is treatment that is given to help keep cancer from coming back after it has disappeared following initial therapy. Daratumumab is in a class of medications called monoclonal antibodies. It binds to a protein called CD38, which is found on some types of immune cells and cancer cells, including myeloma cells. Daratumumab may block CD38 and help the immune system kill cancer cells. Daratumumab is commonly prescribed as initial treatment for patients with AL amyloidosis. However, it is not known what role daratumumab may play in the maintenance therapy period of patients with AL amyloidosis. This phase II trial compares shorter duration maintenance to longer duration maintenance for improving survival in patients with AL amyloidosis.
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Performance status
ECOG 0–3(Limited self-care)
Prior therapy
Must have received: daratumumab-based induction (daratumumab) — induction
Patients must have completed 6 cycles of daratumumab (Dara)-CyBorD-based induction treatment prior to registration or have a plan to complete cycle 6 prior to cycle 1 day 1
Cannot have received: daratumumab maintenance (daratumumab)
Received >1 cycle of daratumumab maintenance after end of induction therapy and prior to registration
Lab requirements
Blood counts
Hemoglobin >= 8.0 g/dL; Absolute neutrophil count (ANC) >= 1000/mm^3; Platelet count >= 50,000/mm^3 (all obtained <= 28 days prior to registration)
Hemoglobin >= 8.0 g/dL (obtained <= 28 days prior to registration); Absolute neutrophil count (ANC) >= 1000/mm^3 (obtained <= 28 days prior to registration); Platelet count >= 50,000/mm^3 (obtained <= 28 days prior to registration)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Mayo Clinic in Arizona · Scottsdale, Arizona
- Mayo Clinic in Rochester · Rochester, Minnesota
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify